 
________________________________________________________________________________________________________ 
  
 
Clinical Study Protocol 
A PHASE 2B, RANDOMIZED , DOUBLE -BLIND , PLACEBO -CONTROLLED STUDY OF EDP-[ADDRESS_1198819] INFECTION WITH RESPI[INVESTIGATOR_860142] (RSVP) 
Protocol Number: EDP 938-[ADDRESS_1198820] number: 2020-001529-30 
IND number 1 3587 4 
  
ClinicalTrials.gov [STUDY_ID_REMOVED] 
  
Protocol Version: 5.0 (Amendment 4.0, Global)
Date: Amendment 4.0 (Global): 20 May 2020 
Amendment 3.0 (Republic of S outh Africa Only): 11 Jan 2020 
Amendment 2.0 (Australia Only): 10 Jan 2020 
Amendment 1.0 (New Zealand Only): 09 Jan 2020 Ori
ginal Protocol: 10 Sep 2019 
  Study Sponsor: Enanta Pharmaceuticals, Inc.  
[ADDRESS_1198821].  
Watertown, MA [ZIP_CODE]  
  Sponsor Medical Monitor:  
Enanta Pharmaceuticals, Inc. [ADDRESS_1198822]. Watertown, MA [ZIP_CODE] 
  
CONFIDENTIAL 
Information and data in this pr otocol contain trade secrets an d privileged or confidential 
information, which is the property of Enanta Ph armaceuticals, Inc. No person is authorized to 
make it public without the written permission of Enanta Pharmaceuticals, Inc.  

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0)  Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_1198823] icable US federal regulation s and Internati onal Council for 
Harmonisation of Technical Re quirements for Pharmaceuticals  for Human Use guidelines. 
 
 
Principal Investigator: 
___________________________________________________________ 
 
Signature: ____________________________ Date: _______________ 
  
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0)  Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_1198824]  Population ................................... 37  
4.2.2  Justification of EDP-938 Dose ......................................................................................... 38  
5. STUDY DRUG AND TREATMENT OF SUBJECTS ............................................................. 41 
5.1 DESCRIPTION OF STUDY DRUG ........................................................................................................ 41  
5.2 PACKAGING AND LABELING  ............................................................................................................ 41  
5.3 STORAGE  ......................................................................................................................................... 41  

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0)  Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 7 of 79  5.4 ACCOUNTABILITY  ............................................................................................................................ 4 1 
5.5 HANDLING AND DISPOSAL  ............................................................................................................... 42  
5.6 TREATMENT ASSIGNMENT /RANDOMIZATION  .................................................................................. [ADDRESS_1198825] AND VISIT SCHEDULE ........................................................................ 47 
7.1 STUDY SITE VISITS  .......................................................................................................................... 47  
7.1.1  Screening Period  on Day 1 ............................................................................................... 47  
7.1.2  Treatment Period (D ays 1 to 5) ........................................................................................ 47  
7.1.3  Follow-up Period (D ays 6 to 14) ...................................................................................... [ADDRESS_1198826] WITHDRAWAL /EARLY TERMINATION  ............................................................................... [ADDRESS_1198827] awal of Subjects........................................................................ 50  
8. STUDY PROCEDURES/EVALUATIONS ............................................................................... 51  
8.1 TIMING OF ASSESSMENTS  ................................................................................................................ 51  
8.2 DEMOGRAPHICS AND MEDICAL HISTORY  ........................................................................................ 51  
8.2.1  Prior and Concomitant  Medications ................................................................................ 51  
8.3 CLINICAL EVALUATIONS  ................................................................................................................. 51  
8.3.1  Vital Sign Mea surements .................................................................................................. 51  
8.3.2  Electrocardi ograms .......................................................................................................... 5 1 
8.3.3  Physical Exam ination ....................................................................................................... 52  
8.3.4  Height, Weight, and Body Mass Index .............................................................................. 52  
8.3.5  Adverse E vents ................................................................................................................ .. 52 
8.3.6  Pulse Ox imetry................................................................................................................. . 52 
8.3.7  Frailty Scal e Score ...........................................................................................................  53 
8.3.8  Respi[INVESTIGATOR_860143] .................................................................... 53  
  
8.3.10  Collection of Nasal and Nasopharyn geal Swabs and Blood Samples .............................. 53  
8.4 LABORATORY AND DIAGNOSTIC PROCEDURES  ................................................................................ 54  
8.4.1  Routine Laboratory Panels ............................................................................................... 54  
8.4.2  Pregnancy and Menopausal Laboratory Testing .............................................................. 54  
8.5 VIROLOGY ASSESSMENTS  ................................................................................................................ 56  
8.5.1  Respi[INVESTIGATOR_14250], Influenza, and SARS-CoV-2 Rapid Molecular 
Diagnostic  Tests............................................................................................................... . 56 
8.5.2  Confirmatory Respi[INVESTIGATOR_13521] y Pathogen Panel ...................................................................... 56  
8.5.3  Respi[INVESTIGATOR_860144] ....................................... 57  
8.5.4  Respi[INVESTIGATOR_860145] (A or B) Determination ........................................ 57  
  
8.5.6  Respi[INVESTIGATOR_860146] ............................................................................... 57  
8.6 PHARMACOKINETIC SAMPLES  .......................................................................................................... 57  

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0)  Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page 8 of 79    
9. SAFETY M
ONITORING AND REPORTING ........................................................................ 59  
9.1 DEFINITIONS  .................................................................................................................................... 59  
9.1.1  Pretreatment  Events .......................................................................................................... 59 
9.1.2  Adverse E vents ................................................................................................................ .. 59 
9.1.3  Serious Adverse  Events ..................................................................................................... 59  
9.2 DOCUMENTING AND REPORTING OF ADVERSE EVENTS (INCLUDING SERIOUS ADVERSE 
EVENTS ) .......................................................................................................................................... 60  
9.2.1  Documenting and Reporting Adverse Events .................................................................... 60  
9.2.2  Assigning Attribution of  Adverse Events ........................................................................... 61  
9.2.3  Classifying Action Take n With Study Drug ....................................................................... 62  
9.2.4  Classifying Adverse Event Outcome ................................................................................. 62  
9.2.5  Documenting and Reporting Serious Pretreatment Events and Serious Adverse 
Events......................................................................................................................... ....... 63  
9.2.6  Documenting and Reporting of Pregnancy ....................................................................... 64  
9.3 FOLLOW -UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  ............................................... 64  
9.4 SPONSOR ’S REVIEW OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  ................................... [ADDRESS_1198828] SAFETY MANAGEMENT/ STUDY STOPPI[INVESTIGATOR_16442] .................................. [ADDRESS_1198829] DISPOSITION AND DEMOGRAPHIC DATA ........................................................................... 68  
11.5 METHOD OF TREATMENT ASSIGNMENT  ........................................................................................... 68  
11.6 EFFICACY ANALYSES  ....................................................................................................................... 68  
11.6.1  Primary Efficacy Analyses ................................................................................................ 68  
11.6.2  Secondary Effica cy Analyses ............................................................................................ 69  
11.7 SAFETY ANALYSES  .......................................................................................................................... 69  
11.7.1  Treatment Co mpliance ...................................................................................................... 69  
11.7.2  Adverse E vents ................................................................................................................ .. 69 
11.7.3  Clinical Labora tory Data ................................................................................................. 70  
11.7.4  Vital Sign Mea surements .................................................................................................. 70  
11.7.5  Electrocardi ograms .......................................................................................................... 7 1 
11.7.6  Pulse Ox imetry................................................................................................................. . 71 
11.7.7  Concomitant Medications ................................................................................................. 71  
11.7.8  Physical Exam inations ...................................................................................................... 71  
11.8 PHARMACOKINETIC ANALYSES  ....................................................................................................... 71  
11.9 SUBGROUP AND COVARIATE ANALYSES  .......................................................................................... 71  
  
11.11  INTERIM ANALYSES  ......................................................................................................................... 72  

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0)  Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
 Page [ADDRESS_1198830] of  the Study ............................................................................................ 73  
12.1.2  Ethical R eview .................................................................................................................. 73  
12.1.3  Written Informed Consent ................................................................................................. 73  
12.1.4  Investigator Co mpliance ................................................................................................... 74  
12.2 DATA COLLECTION  .......................................................................................................................... 74  
12.3 STUDY MONITORING  ....................................................................................................................... 74  
12.4 QUALITY ASSURANCE  ..................................................................................................................... 75  
12.5 RETENTION OF RECORDS  ................................................................................................................. 75  
12.6 INFORMATION DISCLOSURE  ............................................................................................................. 75  
12.6.1  Confiden tiality .................................................................................................................. 75  
12.6.2  Publicatio n Policy ............................................................................................................  76 
13. REFERENCES .................................................................................................................... ......... 77  
14. APPENDICES .................................................................................................................... .......... 78  
APPENDIX 1: SCHEDULE OF ASSESSMENTS  ............................................................................................. 78  
Clinical Study Protocol 
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page [ADDRESS_1198831] OF TABLES 
Table 1: List of Clinical Studies With EDP-938 ............................................................................. 27  
Table 2: Clinical and Respi[INVESTIGATOR_860147] ................................... 55  
Table 3: Options for Action Taken With Study Drug ..................................................................... 62  
Table 4:  Classification and Definition of Adverse Event Outcomes .............................................. [ADDRESS_1198832] OF FIGURES 
Figure 1: Study Design ............................................................................................................................... 36  
 
Clinical Study Protocol 
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page [ADDRESS_1198833] 
EC ethics committee 
EC 50 half-maximal effective concentration 
EC 90 90% maximal effective concentration 
ECG electrocardiogram 
eCOA electronic clinical outcome assessment 
eCRF electronic case report form 
EOS end-of-study 
EOT end-of-treatment 
FDA Food and Drug Administration 
FEV [ADDRESS_1198834] 
IWRS Interactive Web Response System 
LD loading dose 

Clinical Study Protocol 
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page [ADDRESS_1198835] lower limit of normal 
mITT Modified Intent-to-Treat 
MCMC Markov Chain Monte Carlo 
N nucleoprotein 
NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events 
PK pharmacokinetic(s) 
PND postnatal day 
PP Per Protocol 
QTcF QT interval corrected for h eart rate according to Fridericia 
RSV respi[INVESTIGATOR_198632]-qPCR quantitative reverse transc ription polymerase chain reaction 
SAE serious adverse event 
SAF Safety (for the analysis population) 
SAP statistical analysis plan 
SARS-CoV-[ADDRESS_1198836] infection 
WHO World Health Organization 
Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page 13 of 79 
CONFIDENTIAL  
 
 PROTOCOL SUMMARY 
Name [CONTACT_790]/Company: Enanta Pharmaceuticals, Inc. 
Name [CONTACT_791]: EDP-938 
Study Title: A Phase 2b, Randomized, Double-Blind, Pl acebo-Controlled Study of EDP-[ADDRESS_1198837] Infection with 
Respi[INVESTIGATOR_860148] (RSVP) 
Protocol Number:  EDP 938-102 
Phase of Development:  2b 
Study Centers:  This will be a multicente r global study and may include sites in North America, 
South America, Africa, Austra lia/New Zealand, and Europe. 
Number of Subjects Planned:  Approximately 70 subjects will be enrolled. 
Planned Study Population:  Ambulatory, nonhospi[INVESTIGATOR_26328] (aged 18 to 75 years, 
inclusive) with up to [ADDRESS_1198838] infection (URTI) symptoms who test 
positive for respi[INVESTIGATOR_4345] (RSV) a nd negative for influenza virus by [CONTACT_860171] 
(ie, Rapid Viral Screen). Subject s with stable asthma or chro nic obstructive pulmonary disease 
(COPD) will be allowed in the study.  
Investigational Product, Dosage, and Mode of Administration:  EDP-938 will be supplied as 
tablets for oral administrati on :  200 mg. The total dose 
administered will be 800 mg of EDP-938 or placebo once daily for 5 days. 
Duration of Treatment: 5 days  
Study Objectives: 
Primary Objective 
• To evaluate the effect of EDP-[ADDRESS_1198839] ion by [CONTACT_860172] 
• To evaluate the antiviral efficacy of EDP-938  
• To evaluate the pharmacoki netics (PK) of EDP-938  
• To evaluate the safety of EDP-938  

Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page 14 of 79 
CONFIDENTIAL  
 
 Exploratory Objectives  
• To evaluate EDP-938 in terms of emergence of viral resistance 
• To evaluate the relationship between the PK of EDP-938 and antiviral activity and 
clinical symptoms 
• To explore the progression of RSV infect ion using the  
 
• To evaluate the relationship between RSV s ubgroup A or B with antiv iral and clinical 
efficacy of EDP-938 
Criteria for Evaluation:  
Primary Endpoint  
• Effect of EDP-938 compared to placebo on RSV infection clinical sy mptoms measured as 
the total symptom score (TSS) area under the curve (AUC) from Day 1 through Day 14 
Secondary Endpoints 
• The AUC for RSV RNA viral load measur ed in nasopharyngeal swab samples by 
[CONTACT_103201] (RT-qPCR) 
• Percentage of subjects with RSV RNA viral load below the lower limit of quantitation in 
subjects receiving EDP- 938 compared to placebo 
• Plasma PK concentrations of EDP- 938   
 
• Safety endpoints include, but  are not limited to, advers e events (AEs), vital sign 
measurements, pulse oximetry  measurements, and clinical  laboratory test results 
(including chemistry, hema tology, and urinalysis) 
• Time to RSV RNA viral load below the lowe r limit of quantitation in subjects receiving 
EDP-938 compared to placebo 
• RSV RNA viral load change from Baseline 
  
  
  
  
   
Study Design: 
This is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study of EDP-938 
administered orally for the treatment of acute UR TI with confirmed RSV infection in ambulatory 
adult subjects.  

Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page [ADDRESS_1198840] will also 
be provided with a paper di ary(ies) as a back-up. 
The subject will be instructed on the use of c oncomitant medications during the study, including 
the use of acetaminophen as the stud y-specific analgesi c/antipyretic (see Section 5.8 and 
Section 5.9 ). 
Subjects will receive the first dose of study drug while at the study site. After the first dose, 
subjects will be instructed to take 800 mg of EDP-938 or placebo once daily  at approximately the 
same time every day (±1 hour) on each of the [ADDRESS_1198841] orage and transport of study drug.  
On Day 3 and Day 5 (end-of-treatment), subjects should bring their study dr ug with them as part 
of their study site visit (in th e provided cooler system) for dr ug accountability and for dosing of 
study drug on Day 5. If a subject is unable to at tend the Day 3 and/or Day 5 study site visit, a 
home visit by a study nurse may be  arranged, if feasible ; refer to the Study Procedures Manual 
(SPM) for details. 
Subjects who discontinue treatment early (ie, prior to completing 5 days of dosing) should return 
to the study site within 24 hours and no more than 48 hours later to complete the end-of-study 
(EOS) procedures.  
All study assessments during the Tr eatment Period, including PK sa mple collection, are detailed 
in the SoA. 
Follow-up Period (Days 6 to 14): Subjects should return to the study site for follow-up visits on 
Day 9 and Day 14 (EOS Visit) for post-treatment  safety assessments. Visit assessments may be 
completed at the study site or by a study nurse via a home visit, if feasible ; refer to the SPM for 
details. 
Subjects who discontinue the study early (ie, prio r to Day 14) should return to the study site 
within [ADDRESS_1198842] in each study pe riod will be evaluated by 
[CONTACT_860173] y findings, physical examination fi ndings (as applicable), vital 
sign measurements, pulse oximetry measurements (only fo r subjects with asthma or COPD), and 
AEs. 
Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page 17 of 79 
CONFIDENTIAL  
 
 Study Design Figure: 
 
Abbreviations: d = day; FLU = influenza virus; RSV = respi[INVESTIGATOR_4345].  
Eligibility Criteria 
Inclusion Criteria 
Each subject must meet all of  the following criteria to be enrolled into  this study: 
1. A full ICF signed and dated by [CONTACT_423]. (Note:  Prior to signing the full ICF, subjects 
will sign a Rapid Viral Screen ICF as described in inclusion criterion #4.) 
2. Male or female individuals ag ed [ADDRESS_1198843] one of the following symptoms:  
Nasal discharge, nasal congesti on, malaise/tiredness, headache, sinus congestion, 
sneezing, sore throat, hoarseness, cough, shor tness of breath, respi[INVESTIGATOR_860149], earache, 
and/or symptoms of fever. Note: The duration of symptoms (not more th an 48 hours) is to be measured from the 
estimated time of onset of the first symptom. 
4. After signing the Rapid Viral Screen ICF, positive for RSV infection and negative for 
influenza virus based on rapid diagnostic screen of nasal (or nasopharyngeal) swab samples. 
5. Medically stable based on assessment of physi cal examination, medica l history, vital sign 
measurements, pulse oximetry (only for subjects with asth ma or COPD), and 12-lead 
ECG performed at Screening. 
6. A body mass index ≥18 kg/m
2 and ≤40 kg/m2. 
7. Negative urine pregnancy test for women of  childbearing poten tial as defined in 
inclusion criterion #8. 

Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page [ADDRESS_1198844] dose of study drug. Effective methods  of contraception are defined as: 
A condom for the male partner and at least one of the following for the female subject: 
a. Intrauterine device 
b. Occlusive cap (diaphragm or cervical/vault caps) 
c. Oral, injectable, implantable, transdermal, or intravaginal hormonal contraceptive 
Note: The above does not apply to a female su bject who has a vasectomized male as the 
sole partner or who is of nonchildbearing potential (ie, physiologically incapable of 
becoming pregnant) as defined below: 
a. Has had a complete hysterectomy ≥3 months prior to dosing or 
b. Has had a bilateral oophor ectomy (ovariectomy) or 
c. Has had a bilateral tubal ligation or fallopi[INVESTIGATOR_630473] 
d. Is postmenopausal (a total cessation of mens es for at least 2 years; Note: Subjects 
with a cessation of menses between 1 to 2 years and a follicle-s timulating hormone 
[FSH] level of >35 mIU/mL will also be  considered to be postmenopausal). 
9. A male subject who has not had a vasectom y and is sexually active with a woman of 
childbearing potential must agree to use effective contraception from the date of 
Screening to [ADDRESS_1198845] one of th e following for a fe male partner: 
a. Intrauterine device 
b. Occlusive cap (diaphragm or cervical/vault caps) 
c. Oral, injectable, implantable, transdermal, or intravaginal contraceptive 
Note: For a male subject who has had a vasect omy, use of a condom will  still be required. 
10. Male subjects must agree to refrain from sperm donation from the date of Screening until 
[ADDRESS_1198846] be willing and able to adhere to the study assessments, visit sc hedules, prohibitions, 
and restrictions, as desc ribed in this protocol. 
Additional Inclusion Criter ia for Subjects With Asthma 
12. Physician-diagnosed asthma and currently re ceiving Global Initiativ e for Asthma (GINA) 
Step 2, 3, or [ADDRESS_1198847] 4 weeks prior to Screening.  
13. Stable prebronchodilator forced expi[INVESTIGATOR_3741] 1 second (FEV 1) ≥60% of predicted 
within the prior 12 months of Screening based on historical spi[INVESTIGATOR_860150].  
Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page 19 of 79 
CONFIDENTIAL  
 
 Additional Inclusion Criter ia for Subjects With COPD 
14. Physician-diagnosed COPD and currently r eceiving either short-acting bronchodilators 
(as required) or up to two maintenance therapi[INVESTIGATOR_014].  
15. No change in the background COPD therapy fo r at least 4 weeks pr ior to Screening. 
16. Stable postbronchodilator FEV 1 >50% of predicted and FEV 1:forced vital capacity (FVC) 
ratio <0.7 within the prior 12 months of Scr eening based on historical  spi[INVESTIGATOR_860151]. 
Exclusion Criteria  
Subjects will not be eligible to participate in the study if they meet any of the following criteria: 
1. Clinical evidence of a lower respi[INVESTIGATOR_1092], as determined  by [CONTACT_737]. 
2. Anticipated need for hospi[INVESTIGATOR_860152] 24 hours of 
Screening. 
3. Receipt of systemic antiviral,  antibacterial, antifungal, or antimycobacterial therapy 
within 7 days of Screening and for the duration of the study. 
4. Awareness of concomitant respi[INVESTIGATOR_860153] (other than RSV), bacterial, 
or fungal, including systemic b acterial or fungal infections, within 7 days of Screening. 
5. SARS-CoV-2 positive within 28 days of Screening or at Screening following signature [CONTACT_860194]. 
6. Frailty scale score ≥4 at Screening. 
7. History of chronic liver disease (eg, hemo chromatosis, Wilson’s disease, alpha-1 
antitrypsin deficiency, autoimmune hepati tis, nonalcoholic steatohepatitis, and/or 
alcoholic liver disease); a hist ory of biliary disease (eg, prim ary sclerosing cholangitis, 
cholecystitis, choledocholithiasis); or a hi story of portal hypertension. A diagnosis of 
hepatic steatosis (fatty liver) is not exclusionary. 
8. Heart disease: any congenital h eart disease, acute or chronic heart failure, ischemic heart 
disease, congenital long QT syndrome, or a ny clinical manifestat ion resulting in QT 
interval prolongation. Note: Subjects with  controlled hypertensi on without cardiac 
compromise will be allowed to enroll. See exclusion criterion #18 for prohibited 
medications. 
9. Neurological and neurodevelopmental disorders (including disorders of the brain, spi[INVESTIGATOR_36232], peripheral nerve, and muscle, eg, cerebra l palsy, epi[INVESTIGATOR_002] [seizure  disorders], stroke, 
muscular dystrophy, or spi[INVESTIGATOR_1828]). Note: Minor ne urological disorders (eg, past 
concussions, headaches, migraine) are allowed. 
10. Malignant tumor or history of malignancy that may interfere with the aims of the study or 
a subject comple ting the study. 
11. Prior receipt or the subject is waiting to rece ive a bone marrow, stem cell, or solid organ 
transplantation.  
Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page 20 of 79 
CONFIDENTIAL  
 
 12. Diagnosis of cystic fibrosis. 
13. Known positive human immunodeficiency viru s, active hepatitis A virus infection, 
chronic hepatitis B virus infection, and/or current or treated hepatitis C virus infection. 
14. Prior or planned ileal resection or bariat ric surgery. Note: Subj ects who have undergone 
gastric surgeries that do not affect drug absorption (eg, ga stric band or gastric sleeve 
procedures) will be allowed to participate if th ey are stable for at least [ADDRESS_1198848] 3 years prior to Screening. 
15. Pregnant or nursing female subjects. 
16. History of alcohol addiction or  current heavy alcohol use defined as: >[ADDRESS_1198849] drinks 
per week and/or ≥[ADDRESS_1198850] drinks per occasion for males and >[ADDRESS_1198851] drinks per 
week and/or ≥[ADDRESS_1198852] drink is 12 oz of 
beer (5% alcohol), 5 oz table wine (12% alcohol), or 1.5 oz of spi[INVESTIGATOR_17040] s (40% alcohol).  
17. Known or suspected, in the opi[INVESTIGATOR_83781], renal disease or renal impairment. 
18. Twelve-lead ECG demonstrating a QT interval corrected fo r heart rate according to 
Fridericia (QTcF) that is >500 msec or other clinically relevant abnormalities as judged 
by [CONTACT_216813]. 
19. Use of or intention to use excluded or cont raindicated medication(s) or supplements, 
including any medication known to  be a moderate or potent inducer or inhi bitor of the 
cytochrome P450 3A4 enzyme, w ithin 14 days prior to Screening and for the duration of 
the study. 
20. Receipt of ≥14 days of systemic immunomodulator th erapy (eg, oral co rticosteroids) 
within [ADDRESS_1198853] within 30 days or 
5 times the half-life, whicheve r is longer. Note: Influenza vaccination within [ADDRESS_1198854] John’s wort within [ADDRESS_1198855] dose of  study drug and for the 
duration of the study. 
23. History of or currently expe riencing a medical condition or any other finding (including 
laboratory test results) that, in the opi[INVESTIGATOR_689], might  confound the results 
of the study; pose an additional risk in administering study drug to the subject; could prevent, limit, or confound the protocol-spe cified assessments; or deems the subject 
unsuitable for the study.  
Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page [ADDRESS_1198856] experi enced a severe asthma exacerbation (defined as worsening 
asthma that requires treatment with oral cort icosteroids for 3 or more days, or emergency 
room attendance) or deteriorat ion in asthma requiring an increase in asthma treatment for 
at least [ADDRESS_1198857] is receiving more than two main tenance asthma therapi[INVESTIGATOR_860154]. 
26. Pulse oximetry reading of <90% oxygen satu ration measured at rest at Screening. 
Additional Exclusion Criteria for Subjects With COPD 
27. Receipt of theophylline, roflumilast, mainte nance oral corticoste roids, or long-term 
oxygen therapy (defined as prescrib ed for 12 or more hours per day). 
28. Exacerbation of COPD requiring treatment w ith systemic corticosteroids and/or 
antibiotics, or emergency room  attendance or hospi[INVESTIGATOR_21342] [ADDRESS_1198858] 12 months. 
30. Pulse oximetry reading of <90% oxygen satu ration measured at rest at Screening. 
Subject Withdrawal: Subjects may be discontin ued from the study at an y time if the subject, 
Investigator, or Sponsor determines that it is not in the best inte rest of the subject to continue 
participation. Reasons for disc ontinuation include the following: 
• AE 
• Lack of efficacy 
• Lost to follow-up 
• Withdrawal by [CONTACT_1130] 
• Protocol deviation (including noncompliance with study drug or study procedures) 
• Pregnancy 
• Study terminated by [CONTACT_1034] 
• Other 
Statistical Methods: Detailed statistical analysis will be ou tlined in the statistical analysis plan, 
which will be developed and finalized prior to database lock.  
Sample Size Considerations: Using a ratio of 1:1, a sample size of 27 subjects per treatment 
group (54 subjects total) provides 80% power to detect a treatmen t reduction in TSS AUC of at 
least 55% from placebo (assuming TSS AUC from the previous Phase 2a c linical challenge study 
to: mean [standard deviation] of placebo: 500 [450] and EDP-938: 225 [200 ]) using a t-test with 
Protocol Synopsis  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL
 
Page 22 of 79 
CONFIDENTIAL  
 
  
Statistical A
nalysis: Th e following analysis populations are planned:  
Safety (SAF) Population : All subjects who receive at leas t one dose of study drug. Subjects will 
be analyzed in the treatment group that corresponds to the st udy drug received during the study. 
Modified Intent-to-Treat (mITT) Population : All subjects who receive at least one dose of study 
drug. Subjects will be analyzed as treated. The mITT Population is designated as the primary 
efficacy population. 
Per Protocol (PP) Population : All subjects who are randomized a nd receive all planned doses of 
study drug and do not have major protocol de viations that may undul y influence outcome. 
Subjects will be analyzed in the treatment gr oup that corresponds to the study drug received 
during the study. 
Pharmacokinetic (PK) Population : All subjects receiving active study drug and having any 
measurable plasma concentration of study drug at any timepoint. 
Subject Disposition and Demograp hic Data: The number of subj ects screened, randomized, and 
in the SAF, mITT, and PK Populations will be summarized using frequencies and percentages. 
Subject demographics will be summarized by [CONTACT_860174]. Appropriate baseline characteristic s will be included in a ddition to demographic 
characteristics. 
Efficacy Analyses: The primary efficacy analysis will be  performed on the TSS AUC. The TSS 
AUC is measured twice daily (b efore or after treatment, morni ng/evening) using the 13-point 
symptom scale. The AUC will be calculated usin g the trapezoid rule. The TSS will be compared 
between EDP-938 and placebo using an analysis of  covariance (ANCOVA) model with treatment 
group and stratification factor as  fixed effects and the baseline TSS as a covariate. Treatment 
groups will be compared using a type III sum-of-s quares. The least-squares means and two-sided 
95% confidence intervals will be presented for individual groups and the difference between 
groups.  
Sensitivity analysis of the primary endpoint will be performed using the Markov Chain Monte 
Carlo method of multiple imputation. Following imputation, the TSS AUC will be calculated and 
an ANCOVA model with treatment group and strati fication factor as fi xed effects, and the 
baseline TSS as a covariate will be performe d. Treatment groups will be compared using a 
type III sum-of-squares. Other sensitivity analys is may include a mixed model repeated measures 
analysis on the change from Baseline over all visits. 
The RSV RNA viral load AUC measured in nasopharyngeal swab samples by [CONTACT_937]-qPCR will be 
measured on Days 1, 3, 5, 9, and 14. The trapezoid rule will be used to calculate the AUC of the 
RSV RNA viral load. An ANCOVA model with treatme nt group and stratifica tion factor as fixed 
effects and the baseline RSV RNA viral load as a covariate will be performed. Treatment groups 
will be compared using a type III sum-of-squares. The proportion of subjects with RSV RNA 
below the lower limit of quantitation will be an alyzed on Days 3, 5, 9, and 14. Treatment groups 
will be compared using a Cochran-Mantel-Haenszel test controlling for the stratification factor. 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198859] meet all of  the following criteria to be enrolled into  this study: 
1. A full informed consent form (ICF) signed and dated by [CONTACT_423] . (Note: Prior to 
signing the full ICF, subjects will sign a Rapid Viral Screen ICF as described in inclusion 
criterion #4.) 
2. Male or female individuals ag ed [ADDRESS_1198860] infection (URTI) symp toms with at least one of 
the following symptoms:  
Nasal discharge, nasal congesti on, malaise/tiredn ess, headache,  sinus congestion, 
sneezing, sore throat, hoarseness, cough, shortne ss of breath, respi[INVESTIGATOR_860149], earache, 
and/or symptoms of fever. Note: The duration of symptoms (not more th an 48 hours) is to be measured from the 
estimated time of onset of the first symptom. 
4. After signing the Rapid Viral Screen ICF,  positive for RSV infection and negative for 
influenza virus based on rapid diagnostic screen of nasal (or nasopharyngeal) swab 
samples.  
5. Medically stable based on assessment of phys ical examination, medical history, vital sign 
measurements, pulse oximetry (only for subjects with asth ma or chronic obstructive 
pulmonary disease [COPD]), and 12-l ead ECG performed at Screening. 
6. A body mass index (BMI) ≥ 18 kg/m
2 and ≤ 40 kg/m2. 
7. Negative urine pregnancy test for women of ch ildbearing potential as defined in inclusion 
criterion #8. 
8. A woman of childbearing potential who is sexu ally active with a male must agree to use 
two effective methods of cont raception from the date of Scre ening until [ADDRESS_1198861] dose of study drug. Effective methods  of contraception are defined as: 
A condom for the male partner and at least one of the following for the female subject: 
a. Intrauterine device 
b. Occlusive cap (diaphragm or cervical/vault caps) 
c. Oral, injectable, implantable, transdermal, or intravaginal hormonal contraceptive 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 32 of 79 
CONFIDENTIAL  
 
 Note: The above does not apply to a female su bject who has a vasectomized male as the 
sole partner or who is of nonchildbearing potential (ie, physiologically incapable of 
becoming pregnant) as defined below: 
a. Has had a complete hysterectomy ≥3 months prior to dosing or 
b. Has had a bilateral oophor ectomy (ovariectomy) or 
c. Has had a bilateral tubal ligation or fallopi[INVESTIGATOR_630473] 
d. Is postmenopausal (a total cessation of mens es for at least 2 years; Note: Subjects 
with a cessation of menses between 1 to 2 years and a follicle-s timulating hormone 
[FSH] level of >35 mIU/mL will also be  considered to be postmenopausal). 
9. A male subject who has not had a vasectom y and is sexually active with a woman of 
childbearing potential must agree to use effective contraception from the date of 
Screening to [ADDRESS_1198862] one of th e following for a fe male partner: 
a. Intrauterine device 
b. Occlusive cap (diaphragm or cervical/vault caps) 
c. Oral, injectable, implantable, transdermal, or intravaginal contraceptive 
Note: For a male subject who has had a vasect omy, use of a condom will  still be required. 
10. Male subjects must agree to refrain from sperm donation from the date of Screening until 
[ADDRESS_1198863] be willing and able to adhere to the study assessments, visit sc hedules, prohibitions, 
and restrictions, as desc ribed in this protocol. 
Additional Inclusion Criter ia for Subjects With Asthma 
12. Physician-diagnosed asthma and currently re ceiving Global Initiativ e for Asthma (GINA) 
Step 2, 3, or [ADDRESS_1198864] 4 weeks prior to Screening.  
13. Stable prebronchodilator forced expi[INVESTIGATOR_3741] 1 second (FEV 1) ≥60% of predicted 
within the prior 12 months of Screening based on historical spi[INVESTIGATOR_860150]. 
Additional Inclusion Criter ia for Subjects With COPD 
14. Physician-diagnosed COPD and currently r eceiving either short-acting bronchodilators 
(as required) or up to two maintenance therapi[INVESTIGATOR_014].  
15. No change in the background COPD therapy fo r at least 4 weeks pr ior to Screening. 
16. Stable postbronchodilator FEV 1 >50% of predicted and FEV 1:forced vital capacity (FVC) 
ratio <0.7 within the prior 12 months of Scr eening based on historical  spi[INVESTIGATOR_860151]. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198865] Exclusion Criteria 
Subjects will not be eligible to participate in the study if they meet any of the following criteria: 
1. Clinical evidence of a lower respi[INVESTIGATOR_1092], as determined  by [CONTACT_737]. 
2. Anticipated need for hospi[INVESTIGATOR_860152] 24 hours of 
Screening. 
3. Receipt of systemic antiviral,  antibacterial, antifungal, or antimycobacterial therapy 
within 7 days of Screening and for the duration of the study. 
4. Awareness of concomitant resp iratory infections that are viral (other than RSV), 
bacterial, or fungal, includi ng systemic bacterial or fungal infections, within 7 days of 
Screening. 
5. Severe acute respi[INVESTIGATOR_190276] s 2 (SARS-CoV-2) positive within 28 days 
of Screening or at Screening fo llowing signature [CONTACT_860195]. 
6. Frailty scale score ≥4 at Screening. 
7. History of chronic liver disease (eg, hemo chromatosis, Wilson’s disease, alpha-1 
antitrypsin deficiency, autoimmune hepati tis, nonalcoholic steatohepatitis, and/or 
alcoholic liver disease); a hist ory of biliary disease (eg, prim ary sclerosing cholangitis, 
cholecystitis, choledocholithiasis); or a hi story of portal hypertension. A diagnosis of 
hepatic steatosis (fatty liver) is not exclusionary.  
8. Heart disease: any congenital h eart disease, acute or chronic heart failure, ischemic heart 
disease, congenital long QT syndrome, or a ny clinical manifestat ion resulting in QT 
interval prolongation. Note: Subjects with  controlled hypertension without cardiac 
compromise will be allowed to enroll. See exclusion criterion #18 for prohibited 
medications. 
9. Neurological and neurodevelopmental disorders (including disorders of the brain, spi[INVESTIGATOR_36232], peripheral nerve, and muscle, eg, cer ebral palsy, epi[INVESTIGATOR_002] [seizure disorders], 
stroke, muscular dystrophy, or spi[INVESTIGATOR_1828]). Note: Minor neurological disorders 
(eg, past concussions, headach es, migraine) are allowed. 
10. Malignant tumor or history of malignancy that may interfere with the aims of the study or 
a subject comple ting the study. 
11. Prior receipt or the subject is waiting to rece ive a bone marrow, stem cell, or solid organ 
transplantation.  
12. Diagnosis of cystic fibrosis.  
13. Known positive human immunodeficiency viru s, active hepatitis A virus infection, 
chronic hepatitis B virus infection, and/or current or treated hepatitis C virus infection.  
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 34 of 79 
CONFIDENTIAL  
 
 14. Prior or planned ileal resection or bariat ric surgery. Note: Subj ects who have undergone 
gastric surgeries that do not affect drug absorption (eg, ga stric band or gastric sleeve 
procedures) will be allowed to participate if th ey are stable for at least [ADDRESS_1198866] 3 years prior to Screening.  
15. Pregnant or nursing female subjects. 
16. History of alcohol addiction or  current heavy alcohol use defined as: >[ADDRESS_1198867] drinks 
per week and/or ≥[ADDRESS_1198868] drinks per occasion for males and >[ADDRESS_1198869] drinks per 
week and/or ≥[ADDRESS_1198870] drink is 12 oz of 
beer (5% alcohol), 5 oz table wine (12% alcohol), or 1.5 oz of spi[INVESTIGATOR_17040] s (40% alcohol).  
17. Known or suspected, in the opi[INVESTIGATOR_66286], renal disease or  renal impairment.  
18. Twelve-lead ECG demonstrating a QT interval corrected fo r heart rate according to 
Fridericia (QTcF) that is >500 msec or other clinically relevant abnormalities as judged 
by [CONTACT_216813]. 
19. Use of or intention to use excluded or cont raindicated medication(s) or supplements, 
including any medication known to  be a moderate or potent  inducer or inhibitor of 
CYP3A4 enzyme, within 14 days prior to Sc reening and for the dur ation of the study. 
20. Receipt of ≥14 days of systemic immunomodulator th erapy (eg, oral corticosteroids) 
within [ADDRESS_1198871] within 30 days or 
5 times the half-life, whicheve r is longer. Note: Influenza vaccination within [ADDRESS_1198872] John’s wort within [ADDRESS_1198873] dose of  study drug and for the 
duration of the study. 
23. History of or currently expe riencing a medical condition or any other finding (including 
laboratory test results) that, in the opi[INVESTIGATOR_689], might  confound the results 
of the study; pose an additional risk in administering study drug to the subject; could 
prevent, limit, or confound the protocol-spe cified assessments; or deems the subject 
unsuitable for the study.  
Additional Exclusion Criteria  for Subjects With Asthma  
24. Subjects must not have experi enced a severe asthma exacerbation (defined as worsening 
asthma that requires treatment with oral cort icosteroids for 3 or more days, or emergency 
room attendance) or deteriorat ion in asthma requiring an increase in asthma treatment for 
at least [ADDRESS_1198874] is receiving more than two main tenance asthma therapi[INVESTIGATOR_860154]. 
26. Pulse oximetry reading of <90% oxygen satu ration measured at rest at Screening. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198875], mainte nance oral corticoste roids, or long-term 
oxygen therapy (defined as prescribed for 12 or more hours per day).  
28. Exacerbation of COPD requiring treatment w ith systemic corticosteroids and/or 
antibiotics, or emergency room  attendance or hospi[INVESTIGATOR_21342] [ADDRESS_1198876] 12 months. 
30. Pulse oximetry reading of <90% oxygen satu ration measured at rest at Screening. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 36 of 79 
CONFIDENTIAL  
 
 4. STUDY DESIGN  
This is a Phase 2b, randomized , double-blind, placebo-controlle d, multicenter study of EDP-938 
administered orally for the treatment of acute URTI with confirmed RSV infection in ambulatory 
adult subjects. 
The study is composed of 3 periods:  
• Screening Period will occur on Day 1. During this period,  subjects will review and sign 
the Rapid Viral Screen ICF. Subjects will unde rgo a rapid diagnostic screen for RSV and 
influenza virus using respi[INVESTIGATOR_860155] (or nasopharyngeal) swab 
collection. Subjects whose swab sample tests positive for RSV and negative for influenza 
virus will review and sign the full study ICF and may proceed fo r further screening 
procedures. RSV positive and influenza negative subjects will be tested for SARS-CoV-[ADDRESS_1198877] results for SARS-CoV-2 will be excluded from the study. 
• Treatment Period will begin with the first dos e of study drug on Day 1 and will conclude 
with the end-of-treatment (EOT) Visit on Day 5. 
• Follow-up Period for safety will begin follo wing the last dose of study drug and will 
conclude at the end-of-study (EOS) Visit on Day 14, [ADDRESS_1198878] dose of 
study drug.  
4.1 Dose and Treatment Schedule 
Subjects who meet all inclusion crit eria and none of the exclusion criteria will be eligible to enter 
the study and will be randomized 1:1 to receiv e 800 mg of EDP-938 or placebo once daily for a 
total of 5 days. An overview of  the study design is shown in Figure 1 . Study site visits and 
assessments are detailed in the Schedule of Assessments (SoA; Appendix 1).  
Figure 1: Study Design 
 
Abbreviations: d = day; FLU = influenza virus; RSV = respi[INVESTIGATOR_4345]. 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 37 of 79 
CONFIDENTIAL  
 
 4.2 Rationale for Study Design  
This proposed study will evaluate EDP-938 in a dult subjects with confir med RSV, who will be 
randomized to receive either 800 mg of  EDP-938 or placebo in a 1:[ADDRESS_1198879] disease, a prophy lactic agent (palivizum ab) and a therapeutic 
agent (aerosolized ribavirin); each having indicati ons for use that are limited to the pediatric 
population. Analyses performed subs equent to the approval of aeros olized ribavirin suggest that 
it failed to impart any clinically significant benefits (Randolph and Wang, 1996). Consequently, 
physicians have no safe and highl y effective treatment for RSV in fection. This is an issue of 
significant concern for those providi ng medical care for patients at risk of severe RSV disease, 
including the elderly, those with chronic lung and/or he art diseases, immunosuppressed 
individuals, and pediatric patien ts. In these populations, RSV infection may be associated with 
significant morbidity and even mortality. 
This Phase 2b study aims to evaluate the efficacy and safety of EDP-[ADDRESS_1198880] bo in a 1:[ADDRESS_1198881]’s twice daily 
assessment of defined, RSV-rela ted, clinical symptoms over the course of the 14-day study. 
These data will enable the calculation of the AUC for the TSS as was used in the Phase 2a 
EDP 938-[ADDRESS_1198882] a BMI up to 40 kg/m
2, and those with asthma or COPD that is stable and 
less severe by [CONTACT_860175]. Individual s with asthma or COPD are at risk for more 
significant RSV disease. These individuals may be more sensitive to early onset of URTI 
symptoms and thus may be more likely to pr esent for RSV screening. At this stage of 
development, subjects with more severe or unstable asthma or COPD  are excluded from study 
participation. Similarly, the study also excludes s ubjects who are not consid ered to be medically 
stable or who require urgent, emergency medi cal care or hosp italization. Also excluded are 
subjects with known liver, kidney, heart and/or neurologic disease, a nd those who are frail. 
Because the window for optimal in tervention for RSV infection ma y be discrete, the screening 
process is optimized to allow rapid identificatio n of subjects with RS V (but who do not have 
influenza virus) and who are otherwise appropria te for the study so th at EDP-938 (or placebo) 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 40 of 79 
CONFIDENTIAL  
 
  These systemic EDP-938 expos ures are expected to be generally 
safe and efficacious. 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 44 of 79 
CONFIDENTIAL  
 
 the site staff will ask the subjects why any doses were missed, if applicable. Any potential 
reasons for lack of compliance w ith dosing will be monitored and followed up by [CONTACT_7893]. 
Compliance assessment may be co mpleted at the study site or by a study nurse via a home visit, 
if feasible; refer to the SPM for details. 
The time and date of doses of st udy drug taken at the study site shoul d be recorded by [CONTACT_6624]. 
From Day 1, subjects will electron ically record the time and date that each dose is taken. In case 
the subject is unable to complete any assessment s or recordings into the device for technical 
reasons, the subject will also be provided  with a paper diary(ies) as a back-up. 
For any subject considered to demonstrat e continued noncompliance of study drug dosing 
despi[INVESTIGATOR_860156], the Investigator should c ontact the  or the Sponsor’s 
Medical Monitor to discuss possible discontinuation of the subject fro m the study. 
5.[ADDRESS_1198883] abstai n from taking any prohibi ted medications through 
the end of the study (see Section 5.9 ).  
If RSV symptoms occur, such as fever or headac he that require sympto matic relief during the 
study, then subjects may take acetaminophen at a dose of 3000 mg/day or less. Acetaminophen 
will be permitted only for the relief of fever or pain. From Day 1, subjects will electronically 
record the date and time of any acetaminophen use. In case the subject is unable to complete any 
recordings into the device for technical reasons , the back-up paper diar y may be completed by 
[CONTACT_860176]-diagnosed asthma, current GINA Steps 2, 3, or [ADDRESS_1198884] 4 weeks prio r to Screening. The GINA treatment 
guidelines (ie, main report and pocket guide) may be accessed at: https://ginasthma.org/reports/ . 
Administration of more than two maintenance asth ma therapi[INVESTIGATOR_860157].  
For subjects with physician-di agnosed COPD, short-acting bronc hodilators (as required) are 
permitted. No more than two maintenance ther api[INVESTIGATOR_86042]. Receipt of theophylline, 
roflumilast, maintenance oral cort icosteroids, or long-term oxygen therapy (defined as prescribed 
for 12 or more hours per day) will not  be allowed for study participation. 
Details of prior and concomitant medication us e will be recorded in the source documentation 
and the electronic case report form (eCRF) as indicated in the SoA (Appendix 1). 
5.9 Prohibited Medications 
Receipt of systemic antiviral, antibacterial, antifungal, or an timycobacterial therapy within 
7 days of Screening and for th e duration of the study are prohibited. The use of the following 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 46 of 79 
CONFIDENTIAL  
 
 6. BLINDING  
The study will be double-blinded, meaning that the s ubjects, investigators, and site staff will be 
blinded to treatment assignment un til the completion of the study. All site staff will be blinded to 
treatment assignment except for the following individuals:  
• Unblinded Enanta  statistician for purpose of generating and monitoring the 
randomization list 
• Unblinded Enanta representatives not associat ed with the day-to-day conduct of the study 
as outlined in a separate DSMB charter 
• Unblinded members of the DSMB for purposes of unblinded data review 
• Unblinded Drug Supply Chain personnel for the purpose of monitoring drug supplies 
• Enanta Pharmacovigilance Group and Regulatory Affairs representatives when 
required to satisfy regulato ry reporting requirements 
• Bioanalytical laboratory for the purp ose of measuring drug concentrations 
6.[ADDRESS_1198885]’s study treatment is 
necessary for clinical management. In such cases, the Investigator must first attempt to contact 
[CONTACT_860177] s and agree to the need for unblin ding. In situations which the 
Investigator has attempted and fa iled to contact [CONTACT_860178]/or the urgency of 
the case requires immediate acti on, investigators should use thei r best judgment, based on the 
nature and urgency of the clinical situation, and proceed with unblinding. 
For unblinding, in the event that the local Me dical Monitor cannot be reached, sites at all 
locations should call the following 24/7 gl obal medical coverage hotline:  
Once a subject’s treatment assignment has been unblinded for a medical emergency or urgent 
clinical situati on, the  Medical Monitor and study c oordinator should be notified within 
24 hours of unblinding of the trea tment. Information relating to unblinding (eg, the reason, date) 
should be clearly recorded in the subject’s study file. In addi tion, the Investigator should 
consider whether the clinical event that prompted unblinding should be considered an SAE, 
according to the regulatory definitions or criteri a for SAEs, and if so, submit an SAE report as 
described in Section 9.2. 
The  group will also unblind any SAE reports in compliance 
with regulatory reporting require ments. In addition, Enanta Pharmaceuticals, Inc. may unblind 
individual subjects at an y time for matters relating to safety concerns.  
Note: Investigative sites will be provided country-s pecific toll-free telephone and fax numbers.  

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198886] AND VISIT SCHEDULE  
7.1 Study Site Visits 
Details of assessments at each study s ite visit are presented in the SoA (Appendix 1). Also refer 
to the SPM. Study sites will be responsible for following up with subjects for any missed study 
site visits. 
7.1.[ADDRESS_1198887] 
(IRB)- or ethics committee (EC)-approved ICFs and provides authorization to use protected 
health information (see Section 12.1.3). The ICFs will be comple ted prior to conduct of any 
study-specific assessments.  
At Screening (on Day 1), subjects will first review and sign the Rapid Viral Screen ICF prior to 
RSV and influenza screening. Subjects will undergo a rapid diagnostic screen for RSV and 
influenza virus using respi[INVESTIGATOR_860155] (or nasopharyngeal) swab collection; refer to the Laboratory Manual for de tails. Subjects whose swab sample test results 
positive for RSV and negative for influenza viru s may proceed for further screening. Such 
subjects will be required to sign the full study ICF prior to perfor ming any further study-specific 
assessments. After signing the full study ICF, subject s will undergo further sc reening procedures 
to determine study eligibility. 
All study screening activiti es should be completed on Day 1. If any assessment is anticipated to 
fall outside of that window, then the Investigator should consu lt with the  Medical Monitor 
to determine if the subject can proceed. For subjects who sign the full study ICF and whose swab 
sample test results are positive for RSV and nega tive for influenza virus, the first screening 
activity should be to test subjects for se vere acute respi[INVESTIGATOR_6507] 2 
(SARS-CoV-2) using a rapid molecu lar diagnostic test. Subjects wi ll not be randomized until all 
screening activities that allow assessment of inclusion/exclusion criteria have been completed to the satisfaction of the Inves tigator, including the screening ECG and the screening urine 
pregnancy test. 
All screening procedures are detailed in the SoA ( Appendix 1).  
7.1.2 Treatment Period (Days 1 to 5) 
Study Site Visits (Days 1, 3, and 5):  Subjects who meet all inclusion cr iteria and none of the exclusion criteria to the satisfaction of 
the Investigator will be eligible to enter the study and will be randomized 1:[ADDRESS_1198888] ra ndomization will be stratified by [CONTACT_860179]/COPD.  
Eligible subjects must co mplete the Day 1 biological sample  collections (ie, blood, urine, and 
nasopharyngeal swab[s]) prior to  receiving the firs t dose of EDP-938 or placebo. Day 1 blood 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 48 of 79 
CONFIDENTIAL  
 
 and urine samples will be sent to both local (expedited testing and reporting) and central 
laboratories. Nasopharyngeal swab(s) will be sent to the central laboratory only. 
Eligible subjects will receive an elec tronic data capture handheld device (ERT® electronic 
clinical outcome assess ment [eCOA] Handheld eDiary) to use for the duration of the study. 
 
 
The device will also serve to al ert the subject when it is time  for study drug dosing. The subject 
will receive instruction on the pr oper use and care of the device, including the recording of the 
first dose, and the device should be brought to each study site visi t. In case the subject is unable 
to complete any assessments or recordings into  the device for technical reasons, the subject will 
also be provided with a pa per diary(ies) as a back-up. 
The subject will be instructed on the use of c oncomitant medications during the study, including 
the use of acetaminophen as the stud y-specific analgesi c/antipyretic (see Section 5.8 and 
Section 5.9 ). 
Subjects will receive the first dose of study drug while at the study site. After the first dose, 
subjects will be instructed to take 800 mg of EDP-938 or placebo once daily  at approximately the 
same time every day (±1 hour) on each of the [ADDRESS_1198889] will also receive 
instruction on the appropriate stor age and transport of study drug (see Section 5.3 ).  
On Day 3 and Day 5 (EOT), subjects should bring their study drug with them as part of their 
study site visit  for drug accountability and for 
dosing of study drug on Day [ADDRESS_1198890] is unable to attend the 
Day 3 and/or Day 5 study site visit, a home vis it by a study nurse may be arranged, if feasible; 
refer to the SPM for details. It is anticipated that  every reasonable effort will be made to ensure 
that subjects return to the site  for the Day 3 and Day 5 visits. 
Subjects who discontinue treatment early (ie, prior to completing 5 days of dosing) should return 
to the study site within 24 hours and no more  than 48 hours later to complete the EOS 
procedures.  
All study assessments during the Treatme nt Period are detailed in the SoA ( Appendix 1). 
7.1.3 Follow-up Period (Days 6 to 14)  
Study Site Visits (Days 9 and 14):  Subjects should return to the study site for follo w-up visits on Day 9 and Day 14 (EOS Visit) for 
post-treatment safety assessments . Visit assessments may be comp leted at the study site or by a 
study nurse via a home visit,  if feasible; refer to  the SPM for details. 
Subjects who discontinue the study early (ie, prio r to Day 14) should return to the study site 
within 24 hours and no more than 48 hours later to complete th e EOS procedures.  
All study assessments during the Follow-up Period are detailed in the SoA (Appendix 1). 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198891] in each study pe riod will be evaluated by 
[CONTACT_860173] y findings, physical examination fi ndings (as applicable), vital 
sign measurements, pulse oximetry measurements (only fo r subjects with asthma or COPD), and 
AEs. Any subject with ongoing AEs/SAEs at the EOS Visit should be followed up until 
resolution of their AE/SAE or until the Investigator  has determined that the event has stabilized 
as discussed in Section 9.[ADDRESS_1198892] Withdrawal/Early Termination 
Subjects may withdraw from the study at any time at their ow n request, or subjects may be 
withdrawn at any time at the discretion of the In vestigator or Enanta Pharmaceuticals, Inc. for 
safety, behavioral, or administra tive reasons. However, the Inves tigator should c onsult with the 
 Medical Monitor where possible before pr ematurely removing a su bject. For any subject 
who decides to withdraw from th e study, the Investigator should  inquire about the reason for 
withdrawal, request that the subject  returns all unused investigational product(s), re quest that the 
subject returns for a fina l study site visit, if applicable, and follow up with the subject regarding 
any unresolved AEs. Although a subject may disc ontinue the study drug or  the study early, every 
effort must be made for the s ubject to return to the site within [ADDRESS_1198893] to continue participation. Reasons for 
discontinuation include the following: 
• AE 
• Lack of efficacy 
• Lost to follow-up 
• Withdrawal by [CONTACT_1130] 
• Protocol deviation (including noncompliance with study drug or study procedures) 
• Pregnancy 
• Study terminated by [CONTACT_1034] 
• Other 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198894] one dose of 
study drug should return to the site within 24 hours and no more than 48 hours later and undergo 
the EOS procedures per the SoA ( Appendix 1). Any subject who withdraws with ongoing 
AEs/SAEs should be followed up until resolution of their AE(s) or until the Investigator has 
determined that the AE(s) has stabilized. 
Site staff will attempt to contac t any subject who does not return to  the site for the EOS Visit at 
least three times using the s ubject’s preferred method of communication, followed by a letter 
requiring delivery notification if the three attempts were unsu ccessful. Any subject who still 
cannot be reached following those attempts will be considered lo st to follow-up. These subjects 
will be included in the PK and sa fety analysis as indicated in Section 11.3 . 
7.2.3 Documentation of Withdrawal of Subjects 
The reason for early withdrawal/t ermination/lost to follow-up of any subject from the study must 
be documented on the appropriate eCRF. If the reason for early w ithdrawal is an AE or an 
abnormal laboratory value, the specific event or test result, if available, should be recorded on 
the AE eCRF and the subject should be monitored until the event is resolved or deemed stable by 
[CONTACT_737]. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 51 of 79 
CONFIDENTIAL  
 
 8. STUDY PROCEDURES/EVALUATIONS  
8.1 Timing of Assessments 
The timing of assessments is shown in the SoA ( Appendix 1). 
8.[ADDRESS_1198895] 
6 months should be recorded. For events that occurred more than 6 months ago (and that are not 
ongoing), only significant or  relevant events should be ente red on the eCRF. Any items in the 
history that are still ongoing should be noted as such in the eCRF. All surgeries occurring in 
adulthood should be recorded in the eCRF, wher eas surgical methods of contraception, if 
applicable, should only be docum ented in the source documents. 
If there is a question concerni ng a subject’s medical history, then medical records may be 
requested from the subject’s primar y care physician, as appropriate.  
8.2.1 Prior and Concomitant Medications 
Any medication taken during the course of the study through the end of the study will be 
recorded with indication, dosage, route of administration, and start and stop dates of 
administration. All subjects will be  questioned about concomitant medication at each study site 
visit. 
8.3 Clinical Evaluations 
8.3.1 Vital Sign Measurements  
Vital signs include heart rate, respi[INVESTIGATOR_697], systolic and diastolic blood pressure, and body 
temperature. Vital signs will be meas ured at times shown in the SoA ( Appendix 1) after the 
subject has been supi[INVESTIGATOR_2525] a minimum of 5 minutes.  
8.3.2 Electrocardiograms  
A resting 12-lead ECG will be performed locally and recorded at Screening on Day 1 as 
specified in the SoA ( Appendix 1) after the subject has been s upi[INVESTIGATOR_2525] [ADDRESS_1198896] bedside 12-lead ECG machine th at calculates heart rate and measures PR, 
QRS, QT, RR, and QTcF intervals will be utilized.  
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 52 of 79 
CONFIDENTIAL  
 
 At Screening on Day 1, the Investigator or  designee should review the ECG for gross 
abnormalities and interval measurements of concern (absolute readings). The clinical 
interpretation by [CONTACT_860180] a hard copy of 
the ECG (ie, clinically significant or not clinically  significant).  
An ECG may be repeated at the discretion of th e Investigator to address suspected errors in 
performance. Prior to dosing, the screening ECG must  be reviewed to conf irm that no clinically 
significant cardiac abnorma lities are present. 
8.3.3 Physical Examination 
The Investigator or designee will perform the physical examination. A fu ll physical examination 
will be conducted at Screening and will include examination of all pertinent body systems. Any 
subsequent physical examinations performed at the discretion of th e Investigator will be targeted 
to new signs and symptoms including specific as sessments of any changes from previous status. 
Only clinically significant abnor malities should be recorded in  the eCRF (eg, use of contact 
[CONTACT_860181]). 
8.3.[ADDRESS_1198897] in light clothe s and no shoes. Height 
will be documented at Screening only. Body mass index will be calculated at Screening (to 
assess eligibility) according to the following equation: 
BMI = weight (kg)/height (m)2 
These measurements will be obtained as specified in the SoA ( Appendix 1). 
8.3.[ADDRESS_1198898] be recorded in the source doc uments and eCRF as described in Section 9.2 . At all study site 
visits, the Investigator or desi gnee should inquire about the occurrence of AEs. The following are 
examples of open-ended questions  that may be used to obtain this information: “How are you 
feeling?”; “Have you had any medical proble ms recently?”; and “Have you taken any new 
medicines since your last visit/assessment?” 
It is the Investigator’s responsib ility to ensure any necessary additional therapeutic measures and 
follow-up procedures are performed and documen ted in the subject s ource notes and eCRF.  
8.3.[ADDRESS_1198899] pulse  oximetry performed to 
measure oxygen saturation and to ensure study exclusion criteria are not met (see Section  3.2). 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 53 of 79 
CONFIDENTIAL  
 
 Subsequent pulse oximetry measur ements will be performed for s ubjects with asthma or COPD 
as indicated in the SoA ( Appendix 1). 
8.3.[ADDRESS_1198900] udy exclusion criteria are 
not met (see Section 3.2) . Frailty will be assessed by a validated 9-point scale ( Rockwood et al., 
2005) or as otherwise in dicated in the SPM. 
8.3.8 Respi[INVESTIGATOR_860158] ( Appendix 1), subjects will assess the 
severity of RSV-related signs and symptoms  and self-complete the 13-point RSV symptom 
diary. The 13-item diary will consist of grading sy mptoms on a scale of [ADDRESS_1198901] noticeable, Grade 2 is bothersome but does not prevent participation in 
activities, and Grade 3 is bot hersome and interferes with ac tivities. The 13 RSV symptoms 
assessed will comprise nasal discharge, nasal congestion, malaise/tiredn ess, headache, sinus 
congestion, sneezing, sore throat, hoarseness, co ugh, shortness of breath, respi[INVESTIGATOR_860149], 
earache, and/or symptoms of fever. The RSV symp tom diary will be comple ted twice daily at the 
same times each day ±[ADDRESS_1198902] will also be provided with a paper 
diary(ies) as a back-up. If a subject plans to take acetaminophen within [ADDRESS_1198903] ed for virology assessments. The 
RSV-specific tests are indicated in Table 2 . 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 54 of 79 
CONFIDENTIAL  
 
 8.4 Laboratory and Diagnostic Procedures 
At Screening, the rapid viral diagnostic screen  will be performed on s ite. Subsequent virology 
assessments will be sent to the central laboratory(ies). 
On Day 1, enrolled subjects will undergo the clinical laboratory evaluations of blood and urine 
samples specified Table 2 , which will be performed at the loca l site laboratory (expedited testing 
and reporting) and the central laboratory(ies). Su bsequent clinical laboratory evaluations will be 
performed by [CONTACT_2237](ies). The Day 1 collection of blood, urine, and nasoph aryngeal swab samples will be completed prior 
to administration of study drug.  A Laboratory Manual will be provided to the site  detailing kit contents , reordering supplies, 
sample collection, handling, storag e, and shipment instructions. All unblinded laboratory values 
will be reviewed by [CONTACT_737], documente d, and the results maintained in the source 
documents. All out-of-range  laboratory findings require an in terpretation as to whether or not 
they are of clinical significance.  Clinically significant laboratory findings in the opi[INVESTIGATOR_860159] (or SAE as appropriate) (see Section 9.1 ). 
8.4.[ADDRESS_1198904] ed according to the 
SoA ( Appendix 1) and processed as indicated in the Laboratory Manual. Estimated creatinine 
clearance will be calculated using the Cockcroft-Gault equa tion using actual body weight.  
8.4.[ADDRESS_1198905] results will be used to 
qualify subjects at study entry. To confirm nonsurgical postmenopausa l status for women stating that  they are amenorrhoeic for 
1 to 2 years, documentation of FSH levels >35 mIU/mL will be required. Where such 
documentation is not available, then FSH levels  will be measured on Day 1. In such subjects, 
urine and serum pregnancy testing should also be performed at Screening, and these subjects will 
be required to follow appropriate contraceptive practices for women of childbearing potential 
until a confirming FSH level is available. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 55 of 79 
CONFIDENTIAL  
 
 Table 2: Clinical and Respi[INVESTIGATOR_860160], seruma 
Alkaline phosphatase, seruma 
Amylasea 
Aspartate aminotransferasea 
Bilirubin, total and directa 
BUNa 
BUN/Creatinine ratio (calculation) 
Calcium, serum 
Creatine kinase  
Creatinine, seruma 
Creatinine clearance, estimated Uric acid 
Electrolyte panel (sodium, potassium, 
chloride, bicarbonate)
 a 
Phosphorus 
Gamma glutamyl transferase 
Globulin, total 
Glucose, seruma 
Cholesterol 
Triglycerides 
Lactate dehydrogenase Lipase 
Protein, total, serum
 HEMATOLOGY PANEL 
Hemoglobina 
Hematocrita 
Differential white blood cell count, percentage and absolute 
(basophils, eosinophils, lymphocytes, monocytes, neutrophils)a 
Mean corpuscular hemoglobin 
Mean corpuscular hemoglobin concentration 
Mean corpuscular volume 
Platelet counta 
Red blood cell count 
White blood cell counta 
International normalized ratioa 
Prothrombin timea 
Activated thromboplastin timea  
 
RSV-SPECIFIC AND OTHER VIROLOGY TESTS  
RSV and influenza A/B diagnostic test (nasal or nasopharyngeal 
secretions) 
SARS-CoV-[ADDRESS_1198906] (nasopharyngeal or oropharyngeal 
secretions) 
Confirmatory respi[INVESTIGATOR_860161] (nasopharyngeal secretions)  
 
RSV serology (neutralizing antibodies, serum, archived)  
URINALYSIS  
Routine urinalysis to include: Color and 
appearance, pH, specific gravity, bilirubin, 
glucose, ketones, leukocytes, nitrite, occult blood, protein, urobilinogen, microscopic 
examination (including red blood cells and 
white blood cells)
a PREGNANCY AND OTHER TESTS  
Urine pregnancy test  
Serum pregnancy test (only Day 1 and to the central laboratory) 
Follicle-stimulating hormone  
Abbreviations: BUN = blood urea nitrogen; RSV = respi[INVESTIGATOR_4345]. 
a On Day 1, blood and urine samples should be taken from all elig ible subjects and sent to the local laboratory for these identi fied 
tests, which should be assayed and reported in an expedited manner. In parall el, complete hematology, chemistry, and urine 
panels should be sent to the central laboratory with the other Day 1 samples. 
 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 56 of 79 
CONFIDENTIAL  
 
 8.5 Virology Assessments 
Virology assessments and tests (see Table 2 ) will be performed using nasal (or nasopharyngeal) 
swab (rapid diagnostic screen) or  nasopharyngeal swab samples (o ther virology assessments) and 
serology samples collected at Screening a nd at timepoints indi cated in the SoA ( Appendix 1) and 
as further described in the Laboratory Manua l, including swab colle ction, sampling, and 
handling procedures. Note: Multiple nasopharyng eal swab samples may be collected at each 
timepoint; refer to the Laboratory Manual for deta ils. With the exception of  the rapid diagnostic 
test (for RSV and influenza A/B) that will be pe rformed at the local site laboratory, all other 
virology/RSV assessments will be analy zed at the central laboratory(ies). 
8.5.[ADDRESS_1198907] will undergo a rapid 
molecular diagnostic screen for RS V and influenza A/B at the loca l site. Refer to the Laboratory 
Manual for details. A nasal (or nasopharyngeal) swab sample will be collected to obtain 
respi[INVESTIGATOR_171919]. Subjects whose swab sample tests positive for RSV and negative for influenza virus and who agree to proceed, will be required to read and sign the full study ICF and 
may proceed for further screen ing assessments. Results will be  recorded in the source 
documents. 
In the event that the rapid mol ecular diagnostic test is unavailabl e for technical reasons, then 
rapid antigen tests for RSV and influenza virus ma y be used as a back-up. The use of such tests 
and the results must be record ed in the source documents. 
Subjects, who sign the fu ll study ICF and whose swab sample test results are positive for RSV 
and negative for influenza, will be screened fo r SARS-CoV-[ADDRESS_1198908]. 
8.5.2 Confirmatory Respi[INVESTIGATOR_860162] 1, as specified in the SoA ( Appendix 1), eligible subjects will 
have additional nasopharyngeal sw ab sample(s) taken prior to taking the first dose of EDP-938 
or placebo for central laborator y analysis and confirmation of respi[INVESTIGATOR_860163]. 
This testing will be performed to identify othe r nasopharyngeal co-pathogens that may include 
adenovirus, coronavirus, human metapneumovirus,  human rhinovirus/enterovirus, parainfluenza 
virus, Bordetella pertussis , Chlamydophila pneumoniae, and/or Mycoplasma pneumoniae , which 
may impact the course of a subject’s illness. Refe r to the Laboratory Manual for further details. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 57 of 79 
CONFIDENTIAL  
 
 8.5.3 Respi[INVESTIGATOR_860164]-qPCR assay at the 
timepoints specified in the SoA (Appendix 1). The RT-qPCR will also be used to determine viral 
dynamics (eg, peak viral load and time to peak).  Refer to the Laboratory Manual for further 
details. 
8.5.4 Respi[INVESTIGATOR_153606] (A or B) Determination 
Nasopharyngeal swab sample(s) wi ll be analyzed to determine wh ether the virus belongs to RSV 
subgroup A or B. Refer to the Laboratory Manual for fu rther details. 
8.5.5 Viral Resistance 
Nasopharyngeal swab sample(s) may be analyz ed for potential viral resistance monitoring 
assessment. Resistance monitoring assessment, if  performed, will be conducted by [CONTACT_860182]/or deep sequencing of the RS V gene to monitor for treatment-emergent resistance mutations. 
Refer to the Laboratory Manual for further details. 8.5.6 Respi[INVESTIGATOR_860165] ( Appendix 1), samples will be collected for RSV serology 
assessment using the RSV neutra lization antibody assay. Refer to  the Laboratory Manual for 
further details. 
8.6 Pharmacokinetic Samples 
Blood (plasma) samples for PK analysis will be  collected on Day 1 (pos tdose; at least [ADDRESS_1198909] leaves the site, whichever is later), Day 3 (at the same 
approximate time as that of the nasopharynge al swab collection), and Day 5 (predose). 
If the Day [ADDRESS_1198910] should take the study drug at the site duri ng the visit (ref er to the SoA 
[Appendix 1 ]). If the Day [ADDRESS_1198911] takes the study drug pr ior to the study site visit (see Section 5.7 ), a PK sample should 
be taken at the same approxi mate time as that of the nasopharyngeal swab collection. 
At the EOS Visit, a PK sample is only required fo r subjects who discontinue  the study before the 
last dose of study drug is taken. The PK sample should be collected at the same approximate 
time as that of the nasopharyngeal swab collection.  
Blood samples will be collected and processed to  measure plasma concentrations of EDP-938 
 according to the proc edures provided and/or approved by [CONTACT_860183] 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 59 of 79 
CONFIDENTIAL  
 
 9. SAFETY MONITORING AND REPORTING 
9.1 Definitions 
9.1.1 Pretreatment Events 
A pretreatment event is any even t that meets the criteria for an  AE/SAE and occurs after the 
subject signs the ICF but be fore receiving the first administration of study drug. 
9.1.[ADDRESS_1198912] was enrolled in the study are not to be cons idered AEs unless the condition 
deteriorated in an unexpected manner during the study (eg, surger y was performed earlier than 
planned). 
9.1.[ADDRESS_1198913] medical occurrence at any dose that:  
• Results in death: This  includes deaths that appear to be completely unrelated to study 
drug (eg, a car accident)  
• Is a life-threatening event: An event that places  the subject at immediate risk of death at 
the time of the event; it does not refer to an event that hypothetica lly might have caused 
death if it were more severe  
• Requires inpatient hospi[INVESTIGATOR_860166], unless ho spi[INVESTIGATOR_062]: 
o Routine treatment or monitoring of the st udied indication, not associated with any 
deterioration in condition 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198914]’s 
general condition 
• Results in permanent or prolonged (at least 28 da ys in duration) disabi lity or incapacity  
• Is a congenital anomaly or birth defect  in the offspring of a study subject  
• Medically important event: An event that may not be immediately life-threatening, or 
result in death or hospi[INVESTIGATOR_059], or require  intervention to preven t one of the outcomes 
listed above but is considered medically sign ificant for other reasons. An opportunistic or 
otherwise unusual infec tion for the Investigato r’s practice, such as tuberculosis, will be 
considered medically significant.  
The term severe is used to desc ribe the intensity of a specific event (as in mild, moderate, or 
severe); the event itself, howev er, may be of minor medical significance (such as severe 
headache). This is not the same as serious, which is based on outcome of the event, as described 
above. Seriousness, not intensity, serves as a guide for defining regulat ory reporting obligations. 
9.2 Documenting and Reporting of Adverse Events (Including Serious Adverse Events) 
Adverse events will be evaluated and documented using the grading scales contained in the National Cancer Institute Common Terminolog y Criteria for Adverse Events (NCI-CTCAE) 
Version 4.03. 
9.2.[ADDRESS_1198915]’s source documents. Fo r subjects who do not receive study drug (ie, 
alternates or screen failures), AEs will only be recorded in the source do cuments. For subjects 
enrolled into the study (ie, random ized), all AEs will be recorded in the subject’s AE eCRF and 
the SAE Form (if applicable). The AE eCRF will i ndicate if the event occurred prior to the first 
dose of study drug, during treatment, or during the postdose Follow-up Period. The site should 
record all AEs regardless of the intensity, seriousness, or rela tionship to study drug. 
Adverse events (serious and nonserious) will be  graded in accordan ce with the NCI-CTCAE 
scale as follows:  
• Mild  (Grade 1): asymptomatic or mild sympto ms; clinical or diagnostic observations 
only; interventi on not indicated 
• Moderate  (Grade 2): minimal, local or noninvasive interven tion indicated; limiting 
age-appropriate instrumental  activities of daily living 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 61 of 79 
CONFIDENTIAL  
 
 • Severe  (Grade 3): severe or medically significant but not immediately  life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self-care 
activities of daily living 
• Life-threatening  (Grade 4): life-threatening conseque nces; urgent intervention indicated  
• Death (Grade 5): death re lated to the AE 
Any recurrence of an AE with similar causality to study drug will be reported as recurrence or 
exacerbation of the initial event, and not as a new event. Whenever possible, AEs will be 
reported as a specific diagnosis or  syndrome (eg, flu syndrome) rather  than as individual signs or 
symptoms. If no specific diagnosis or syndrome is identified, AEs should be reported as separate 
and individual events.  
An AE includes the following:  
• Progression or exacerbation of the subject’s underlying diseas e. Clinical sequelae that 
result from disease progression, such as pleural effusion or small bowel obstruction, are 
reportable as AEs  
• Pre-existing event that increases  in frequency or intensity  
• Condition detected or diagnosed during the study period, even though it may have been 
present, in retrospect, prior to the first dose of study drug 
• Laboratory abnormalities outside of normal limits with associated clinical symptoms or 
suspected latent clinical symptoms in the opi[INVESTIGATOR_689], including those 
requiring therapeutic intervention 
• An overdose of the study drug without any signs or symptoms will be considered an AE. A calculated dose that exceeds its correct dose by 10% or more and is administered to the 
subject will be considered an ove rdose and documented as an AE  
The following events will not be identified as AEs in this study:  
• Medical or surgical procedures (eg, surg ery, endoscopy, tooth extr action, etc); however, 
the condition (the “triggering event”) that leads to the procedure may be an AE  
• Pre-existing conditions present or  detected prior to the first dose of study drug that do not 
worsen 
9.2.[ADDRESS_1198916] attempt to determine the cause  of each event. Every effort will be made by 
[CONTACT_153686]. To ensure consistency of 
AE/SAE causality assessments, the Investigat or should apply the fo llowing guidelines:  
• Related:  There is an association between the event and the adminis tration of study drug, 
a plausible mechanism for the ev ent to be related to the study drug and causes other than 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198917] been ruled out, and/or the event reappeared on re-exposure to the 
study drug.  
• Possibly related:  There is an associati on between the event and th e administration of the 
study drug and there is a plausi ble mechanism for the event to be related to study drug, 
but there may also be alternative etiology, such as characteristics of the subject’s clinical 
status or underlying disease.  
• Unlikely related:  The event is unlikely to be related to the study drug and likely to be 
related to factors other than study drug.  
• Not related: The event is related to an etiology ot her than the study dr ug (the alternative 
etiology must be documented in th e study subject’s medical record). 
9.2.3 Classifying Action Taken With Study Drug 
In the case of an AE, the actions that can be taken with study drug are defined in Table 3 . 
Table 3: Options for Action  Taken With Study Drug 
Classification  Definition  
Dose Not Changed  Study drug dose not changed in response to the adverse event  
Drug Interrupted  Study drug administration interrupted in response to an adverse event  
Drug Withdrawn  Study drug administration permanently disc ontinued in response to an adverse 
event  
Not Applicable  Action taken regarding study drug administ ration does not apply. “Not applicable” 
should be used in circumstances when no  opportunity to decide whether to 
continue, interrupt, or withdraw treatment was possible such as when the 
investigational treatment had been comple ted before the adverse event began.  
9.2.4 Classifying Adverse Event Outcome 
For every AE/SAE, the possible outcomes of the event and the definition of the outcome are 
shown in Table [ADDRESS_1198918] be entered into th e appropriate field on the AE and (if 
appropriate) SAE Form for each event as  discussed in the eCRF instructions. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198919] SAFETY MANAGEMENT/ STUDY STOPPI[INVESTIGATOR_340977]  
10.[ADDRESS_1198920] aced on hold pending a full review of all available 
clinical safety data and discussion with the investigators and the DSMB. 
• Two or more subjects receiving EDP-938 experience a similar Grade 3 study drug-related 
AE, including a confirmed treatment-emergent Grade 3 laborato ry abnormality  
• One or more subjects receiving ED P-938 experience a study drug-related SAE 
• One or more subjects receiving EDP-[ADDRESS_1198921] udy at any time. Reasons for terminating the study 
may include, but are not lim ited to, the following: 
• The incidence or severity of AEs in this  study indicates a poten tial health hazard to 
subjects 
• Subject enrollment is unsatisfactory 
• Data recording is inaccurate or incomplete 
• Investigator does not adhere to the protocol or applicab le regulatory guidelines in 
conducting the study 
• A decision from the IRB/EC or regulatory authority to terminate the study 
If the study is suspended or ter minated for safety reasons, Enan ta Pharmaceuticals, Inc. will 
promptly notify the investigators and will also info rm the regulatory authorities of the suspension 
or termination of the study and the reasons for the action. The I nvestigator is responsible for 
promptly informing the IRB/EC and providing the reasons for the suspension or termination of 
the study. 
10.2.2 Site Termination 
A single site may warrant termin ation under the following conditions: 
• Failure of the site to enroll subjects in to the study at an acceptable rate 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 66 of 79 
CONFIDENTIAL  
 
 • Failure of the site to comply with pertin ent governmental regula tions as appropriate 
• Submission of knowingly false information from the research  facility to the Sponsor, 
Clinical Monitor, or governmental authority 
• Failure to adhere to the protocol requirements 
• Data recording is inaccurate or incomplete 
• Investigator does not adhere to the protocol or applicab le regulatory guidelines in 
conducting the study 
10.2.[ADDRESS_1198922]  be conducted by [CONTACT_153687]/or site staff: 
• Return of all study data to Enanta  Pharmaceuticals, Inc. or designee 
• Respond to and complete all requests for data clarifications 
• Accountability and final dispositi on of used and unused study drug 
• Review of site records for completeness 
• Shipment of all applicable biological sample s (including PK samples) to the designated 
laboratory 
 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 67 of 79 
CONFIDENTIAL  
 
 11. STATISTICAL CONSIDERATIONS 
11.1 General Considerations 
Statistical analysis of this study will be the responsibility of Enanta Pharma ceuticals, Inc. or its 
designee. Details of the statistical analysis meth ods will be described in the statistical analysis 
plan (SAP) document.  
Continuous endpoints will be summarized usi ng n, mean, standard deviation, median, 
25th quartile, 75th quartile, minimum, and ma ximum values. Categorical endpoints will be 
summarized by [CONTACT_860184] e endpoint and the percen tage of subjects out 
of the appropriate population. The denominator will be displayed when needed. Statistical 
inference will be performed as appropriate. Inferential testing will be conducted using a 
two-sided alpha of 0.05, unless stated otherwise.  Any change to the data analysis methods describe d in the protocol will require an amendment if 
it changes a principal feature of the protocol. Any other change to the data analysis methods 
described in the protocol, and th e justification for making the ch ange, will be described in the 
clinical study report or SAP. Changes may only be made in the SAP prior to unblinding. 
11.2 Sample Size Considerations 
Using a ratio of 1:1, a sample si ze of 27 subjects per treatment gr oup (54 subjects total) provides 
80% power to detect a treatment  reduction in TSS AUC of at least 55% from placebo (assuming 
TSS AUC from the previous Phase 2a clinical cha llenge study to: mean [standard deviation]) of 
placebo: 500 [450] and EDP-938: 225 [200]) using a t-test with unequal variance. Assuming a 
20% dropout rate, approximately  35 subjects per treatment group (approximately 70 subjects 
total) are needed. 
11.3 Analysis Populations 
The following analysis popul ations are planned:  
• Safety (SAF) Population : All subjects who receive at  least one dose of study drug. 
Subjects will be analyzed in the treatm ent group that corresponds to the study drug 
received during the study. 
• Modified Intent-to-Treat (mITT) Population : All subjects who receiv e at least one dose of 
study drug. Subjects will be analyzed as tr eated. The mITT Populati on is designated as 
the primary efficacy population. 
• Per Protocol (PP) Population : All subjects who are randomiz ed and receive all planned 
doses of study drug and do not have major protocol deviatio ns that may unduly influence 
outcome. Subjects will be analyzed in the tr eatment group that corresponds to the study 
drug received during the study. 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 68 of 79 
CONFIDENTIAL  
 
 • Pharmacokinetic (PK) Population : All subjects receiving active study drug and having 
any measurable plasma concentratio n of study drug at any timepoint. 
11.[ADDRESS_1198923] disposition:  
• Completed study drug per the protocol  
• Discontinued study drug early and the reason for discontinuation  
• Completed the study  
• Discontinued from the study early an d the reason for discontinuation  
Subject demographics will be summarized by [CONTACT_860185]. Appropriate baseline characteristics will be included  in addition to demographic 
characteristics. No statistical testing will be performed. 
11.5 Method of Treatment Assignment 
Subjects who meet all cr iteria for enrollment will  be randomized to bli nded treatment on Day 1 
in a 1:[ADDRESS_1198924]. To achieve between-g roup comparability, the 
randomization will be stratified by [CONTACT_4221]/COPD status. 
11.6 Efficacy Analyses  
11.6.1 Primary Efficacy Analyses 
The primary efficacy analysis will be performed  on the TSS AUC. The TSS AUC is measured 
twice daily (before or after treatment, morning/evening) using the 13-point symptom scale. Date 
and time of completion and symptom severity (gra ded 0 to 3) will be recorded. The TSS will be 
derived for each from the last nonmissing measurement (Baseline) collected prior to dosing to 
the final on Day 14. The average daily TSS will be computed as part of the primary efficacy 
endpoint. The AUC will be calculated using the trapezoid rule ( Matthews et al., 1990 ). The TSS 
will be compared between EDP-938 and placebo using an analysis of covariance (ANCOVA) 
model with treatment group and st ratification factor as  fixed effects and the baseline TSS as a 
covariate. Treatment groups will be compared us ing a type III sum-of-squares. The least-squares 
means and two-sided 95% confidence intervals (C I) will be presented for individual groups and 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 69 of 79 
CONFIDENTIAL  
 
 the difference between groups. Desc riptive statistics will include at a minimum the number of 
nonmissing measurements, mean, median, minimum, maximum, and 95% CI for the mean. 
11.6.2 Secondary Efficacy Analyses 
Sensitivity analysis of the primary endpoint will be performed using the Markov Chain Monte 
Carlo (MCMC) method of multiple imputation ( Dong and Peng, 2013). Following imputation 
using MCMC methods, the TSS AUC will be calc ulated and an ANCOVA model with treatment 
group and stratification factor as  fixed effects, and the baselin e TSS as a covariate will be 
performed. Treatment groups will be compared usi ng a type III sum-of-squares. Other sensitivity 
analysis may include a mixed model repeated measures analys is on the change from Baseline 
over all visits. 
The RSV RNA viral load AUC measured in nasopharyngeal swab samples by [CONTACT_937]-qPCR will be 
measured on Days 1, 3, 5, 9, and 14. The trapezoid rule will be used to calculate the AUC of the 
RSV RNA viral load. An ANCOVA model with treatme nt group and stratifica tion factor as fixed 
effects and the baseline RSV RNA viral load as a covariate will be performed. Treatment groups 
will be compared using a type III sum-of-squares. The proportion of subjects with RSV RNA 
below the lower limit of quantitation will be an alyzed on Days 3, 5, 9, and 14. Treatment groups 
will be compared using a Cochran-Mantel-Haenszel test controlling for the stratification factor. 
11.7 Safety Analyses 
Statistical methods for the safety  analyses will be primarily desc riptive in nature. Safety data, 
including AEs, vital sign measurements, pulse  oximetry (only for subjects with asthma or 
COPD), concomitant medications , and laboratory values, will be  summarized separately by 
[CONTACT_1570]. Change from Baseline will be included in summary ta bles for vital sign 
measurements and laboratory parameters. Shift tables will also be generated by [CONTACT_860186]. All laboratory data will be included in the data listings, and all test valu es outside the 
normal range will be flagged. 
11.7.[ADDRESS_1198925] w ill be calculated as the number of subjects 
receiving the amount of drug taken divided by [CONTACT_860187] 100. 11.7.2 Adverse Events 
Adverse events will be summarized by [CONTACT_860188]. All subjects in the SAF Population will be 
included in the summaries. Treatment-emergent AEs (TEAEs) are defined as reported AEs that 
first occurred or worsen ed during the post-Baseline phase co mpared to Baseline. The maximum 
severity at Baseline will be  used as baseline severity. If the maximum severity during 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198926]-Baseline is greater than the maximum baseline severity, then the event is considered 
treatment emergent. No statistica l testing will be performed.  
Summaries of AEs will include the following at a minimum:  
• An overall summary of AEs with a line for each of the categories provided below:  
o TEAEs  
o Related TEAEs  
o Maximum severity TEAE  
o TEAEs by [CONTACT_926]  
o TEAEs leading to stu dy drug discontinuation  
o AEs leading to death  
o SAEs  
o Related treatment- emergent SAEs  
11.7.[ADDRESS_1198927] = lower limit of normal and ULN = upper limit of normal.  
For categorical tests: Treatment-emergent abnor mal is defined as a change from normal at 
Baseline to abnormal at a ny post-Baseline visit.  
For continuous tests: 
• Treatment-emergent high is defi ned as a change from a result  less than or equal to the 
high limit at Baseline to a va lue greater than the high limi t at any time post-Baseline. 
Results will be reported according to any valu e greater than the high limit, any value 
greater than 2× ULN and 3× ULN.  
• Treatment-emergent low is defined as a change from a result greater th an or equal to the 
low limit at Baseline to a value less than the low limit at any time post-Baseline.  
Results will be reported to any value less th an the lower limit, any value less than 
2× LLN and 3× LLN. 
11.7.[ADDRESS_1198928]-Baseline 
visit will be summarized. Specific criteria for th e classification of treatment emergent will be 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198929] World Health Organization (W HO) Anatomical Therapeutic Chemical (ATC) 
Classification level 4 and WHO preferred term . Summaries will be provided by [CONTACT_479521] 4 
and preferred term. Subjects in the SAF Population will be summarized by [CONTACT_1570]. 11.7.8 Physical Examinations 
Physical examination data will be provided in data listings. 11.8 Pharmacokinetic Analyses 
Summary of plasma concentration data will be descriptive in nature. Available plasma 
concentration-time data in the PK Population will be summ arized by [CONTACT_1570]. Mean 
plasma concentration-time figur es may be created for EDP-938 , as allowed 
by [CONTACT_26739]. Additional details wi ll be provided in the SAP. 
11.9 Subgroup and Covariate Analyses 
Subgroup analyses will be performed on the primary and secondary endpoints, primarily. A 
logistic regression model will be planned when  categorical endpoints are analyzed. The model 
will include treatment group and stratification factor as fixe d effects, with subgroup and 
subgroup-by-treatment interaction as well. Odds ratios and 95% CI will be reported. For continuous endpoints, an ANCOVA model with treatme nt group and stratifica tion factor as fixed 
effects in the model, with subgroup and s ubgroup-by-treatment in teraction as well. 
Various study populations may be used. Forest pl ots will be provided to visually describe the 
association. 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 72 of 79 
CONFIDENTIAL  
 
  
 
11.11
 Interim Analyses 
No interim analysis will be  performed in this study. 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198930] of the Study 
The study will be conducted in compliance with th is protocol, principles of E6 Good Clinical 
Practice: Consolidated Guidance (ICH-GCP), Declar ation of Helsinki, and all applicable local 
laws and regulations gover ning clinical  studies. 
12.1.2 Ethical Review 
It is the Investigator’s responsibil ity to ensure that this protocol  is reviewed and approved by [CONTACT_153691]/EC that confor ms to the regulations set fort h in FDA 21 Code of Federal 
Regulations (CFR) Part [ADDRESS_1198931], and all advertisements that may be used  for study-specific recruitment to the IRB/EC for 
review and approval before commencing study-speci fic assessments. If it is necessary to amend 
the protocol during the study, then it is the respon sibility of the Investig ator to ensure that 
IRB/EC approval is obtained befo re implementation of the amende d procedures. It is also the 
responsibility of the Investigator to provide the IRB/EC with any SAE or Investigational New 
Drug safety reports. A copy of the ICF approved by [CONTACT_1201]/EC must be forwarded to Enanta 
Pharmaceuticals, Inc. for regulatory purposes.  
12.1.[ADDRESS_1198932] remain in each subjec t’s study file and be available fo r verification by [CONTACT_860189]. In accordance with individual local  and national subject privacy regulations, the 
Investigator or designee must expl ain to each subject prior to Scr eening that for the evaluation of 
study results, the subject’s protect ed health information obtained during the study may be shared 
with Enanta Pharmaceuticals, Inc. and its desi gnees, regulatory agencies, and IRBs/ECs. As the 
study Sponsor, Enanta Pharmaceuticals, Inc. wi ll not use the subjec t’s protected health 
information or disclose it to a third party without a pplicable subject aut horization. It is the 
Investigator’s or designee’s responsibility to ob tain written permission to use protected health 
information from each subject, or  if appropriate, the subject’s legal guardian. If a subject or 
subject’s legal guardian withdraw s permission to use protected h ealth information, it is the 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 74 of 79 
CONFIDENTIAL  
 
 Investigator’s responsibility to obtain the withdrawal request in writing from the subject or 
subject’s legal guardian and to en sure that no further data will be collected from the subject. Any 
data collected on the subject prior to withdrawal will be used in the analysis of study results.  
12.1.[ADDRESS_1198933] udy (ie, efficacy assessments) will 
require IRB/EC notification prio r to implementation, except where the modification is necessary 
to eliminate an apparent immedia te hazard to human subjects.  
If circumstances require an immediate departure fr om protocol procedures , the Investigator will 
contact [CONTACT_153669], Inc. and/or its designee to disc uss the planned course of action. 
Contact [CONTACT_860190]. Any 
departures from protocol must  be fully documented in the so urce documents and reported to 
Enanta Pharmaceuticals, Inc. or its designee and the IRB/EC as required.  
12.[ADDRESS_1198934] will be entered into an eCRF by [CONTACT_6624]. It is the 
Investigator’s responsibility to ensure the accuracy, completeness, clarity, and timeliness of the 
data reported in the subject’s eCRF. Source documentation supporting the eCRF data should 
indicate the subject’s participation in the st udy and should document the dates and details of 
study procedures, AEs, other obser vations, and subject status. Th e Investigator or designated 
representative should comp lete the eCRF as soon as possible after information is collected. An 
explanation should be provi ded for all missing data. 
After the subject has completed the study, the Investigator must review and sign the signature 
[CONTACT_860196], to the best  of his or her knowledge, all data recorded in the 
eCRF accurately reflects the subject’s  clinical performance in the study.  
Sites are responsible for abiding by [CONTACT_860191] I RB/EC for recording and 
reporting protocol deviations. All de viations reported to the IRB/EC  must be reported to Enanta 
Pharmaceuticals, Inc. and/or their designee and recorded as deviations as appropriate in the 
eCRF. 
12.3 Study Monitoring 
Representatives of Enanta Pharmaceuticals, In c. or its designee will monitor this study until 
completion. Monitoring will be conducted throug h both on-site and remote visits with the 
Investigator and site staff as  well as any appropriate communi cations by [CONTACT_2319], fax, email, or 
telephone. The purpose of monitoring is to ensure  compliance with the protocol and the quality 
and integrity of the data. The Study Monitor will  ensure that the inve stigation is conducted 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 75 of 79 
CONFIDENTIAL  
 
 according to protocol and regulatory requirement s, and as described in the Study Monitoring 
Plan. 
Every effort will be made to maintain the anonymity and confid entiality of all subjects during 
this clinical study. However, because of the experimental nature of this treatment, the 
Investigator agrees to allow the IRB/EC, repres entatives of Enanta Pharmaceuticals, Inc., its 
designated agent, and authorized employees of the appropriate regulatory agencies to inspect the 
facilities used in this study and, for purposes of verification, allow direct access to the hospi[INVESTIGATOR_153651]. A statement to this effect will be 
included in the ICF authorizing the us e of protected health information. 
12.[ADDRESS_1198935] access to all source documents, eCRFs, and other study documentation for 
source data check and/or on- site audit inspection.  
12.[ADDRESS_1198936] name [CONTACT_54798] (eg, unit discharge 
summary), it must be obliterated before the docu ment is transmitted to Enanta Pharmaceuticals, 
Inc. or its designee. All study findings will be stor ed in electronic databases. As indicated in the 
ICF, subjects will give permission for representatives of the Sponsor, regulatory authorities, and 
the IRB/EC to inspect their medical records to verify the information collected. Subjects will be 
informed that all personal in formation made available for in spection will be handled in the 
strictest confidence and in accordance w ith local data protection/privacy laws. 

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198937]’s personal 
physician or other appropriate me dical personnel when required in  connection with the subject’s 
continued health and welfare and with the subject’s prior knowle dge and permission. 
12.6.[ADDRESS_1198938] disclosed.  
All information generated from this study is the proprietary pr operty of Enanta Pharmaceuticals, 
Inc. Enanta Pharmaceuticals, Inc. rese rves the right, among other things, to: 
• Modify or amend study material to ensure that no confidenti al or proprietary information 
is disclosed 
• Ensure that the reported da ta are factually correct 
• Utilize the information generated from or as a result of this study in any manner it deems 
appropriate, including but not limited to regulatory submissions, annual reports, and other 
scientific or business affairs of the company 
• Modify the publication or disc losure or delay it a sufficient time to allow Enanta 
Pharmaceuticals, Inc.to seek patent prot ection of any inventio n contained therein 
 
Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page [ADDRESS_1198939] ication inhibitor of 
respi[INVESTIGATOR_4345]: final results of a Phase 1 study in hea lthy subjects (HS). Poster session 
presented at: 11th International Respi[INVESTIGATOR_853536]; [ADDRESS_1198940] 31-Nov 4, Asheville, 
NC. 
Dong Y, Peng C-YJ. Principled missing data methods for resear chers. SpringerPlus. 2013;2:222. 
Available at: https://springerplus.springe ropen.com/track/pdf/ 10.1186/2193-1801-2-222. Accessed 
21 Aug 2019.  Falsey AR, Hennessey PA, Formica MA, et al. Respir atory syncytial virus infection in elderly and 
high-risk adults. N Engl  J Med. 2005;352(17):1749-59. 
Hall CB, Weinberg GA, Iwane MK, et al. The burden of respi[INVESTIGATOR_667122]. N Engl J Med. 2009;360(6):588-98. 
Matthews JN, Altman DG, Campbell MJ, et al. Analysis  of serial measurements in medical research. 
BMJ. 1990; 300(6719): 230-5. 
Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respi[INVESTIGATOR_860167]: a sy stematic review and meta-analysis. Lancet. 
2010;375(9725), 1545-55. 
 
 
 
 
 
Randolph AG, Wang EE. Ribavirin for respi[INVESTIGATOR_860168]. A 
systematic overview. Arch Pedi
atr Adolesc Med. 1996;150(9):942-7. 
Rockwood K, Song X, MacKnight C, et al. A global cl inical measure of fitne ss and frailty in elderly 
people. CMAJ. 2005;173(5):489-95.  Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of 
acute lower respi[INVESTIGATOR_860169] 2015: a 
systematic review and modelli ng study. Lancet. 2017;390([ZIP_CODE]):946-58. 
Shook BC, Lin K. Recent advances in developi[INVESTIGATOR_860170]. Top 
Curr Chem (Cham); 2017:375(2):40.  

Clinical Study Protocol  
EDP 938-102 v5.0 (Amendment 4.0) Enanta Pharmaceuticals, Inc. 
CONFIDENTIAL 
 
Page 79 of 79 
CONFIDENTIAL  
 
  a Day 1 assessments to be performed in randomized subjects.  
b Subjects who discontinue treatment early (ie, prior to completin g 5 days of dosing) or the study  early (ie, prior to Day 14) s hould return to 
the study site within 24 hours and no more than 48 hours later to complete the EOS procedures.  
c Visit assessments may be completed at the study site or by a study nurse via a home vi sit, if feasible; refer to the SPM for d etails. It is 
anticipated that every reasonable effort will be made to ensure that subjects return to the site for the Day [ADDRESS_1198941] udy-specific assessments. For this study, there will be two ICFs. Subjects 
will review and sign the Rapid Viral Screen ICF prior to RSV an d influenza screening. Subjects whose swab sample tests positive  for 
RSV and negative for influenza virus may pro ceed for further screening. Such subjects w ill be required to sign the full study I CF prior to 
performing any further study-specific assessm ents. After signing the full study ICF, s ubjects will undergo further screening pr ocedures to 
determine study eligibility.  
e A nasal (or NP) swab sample will be collected to obtain respir atory secretions for a rapid dia gnostic screen for RSV and influ enza A/B. 
f Subjects who sign the full study ICF and whos e swab sample test results are positive fo r RSV and negative for influenza will b e screened 
for SARS-CoV-2, using a rapid diagnostic test.  
g Vital signs include heart rate, respi[INVESTIGATOR_13521] y rate, systolic and diastolic blood pressu re, and body temperature. Vital signs wil l be measured 
after the subject has been supi[INVESTIGATOR_2525] a minimum of 5  minutes. 
h A full physical exam ination will be performed at Screeni ng. Any subsequent physical examinat ions performed at the discretion o f the 
Investigator will be targeted to new signs and symptoms, incl uding specific assessments of any changes from previous status. 
i Height will be documented at Screening only. Body mass index w ill be calculated at Screening (t o assess eligibility) according  to the 
following equation: BMI = weight (kg)/height (m)2. 
j Pulse oximetry measurements should only be pe rformed in subjects with asthma or COPD.  
k Pregnancy testing will be performed in fe male subjects of childbearing potential. A urine pregnancy test will be performed at Screening 
and at the EOS Visit. In addition, on Day 1, blood will be collected for a serum pregnancy test to be performed by [CONTACT_2237]. 
The screening urine pregnancy test results will be used to qualify subjects at study entry. Refer to Section 8.4.2 for pregnancy testing 
requirements for postme nopausal females. 
l Follicle-stimulating hormone should be tested in postmenopausal females. Refer to Section 8.4.2 . 
m Clinical laboratory tests include chemistry, hematology, and urinalysis. See Section 8.4  and Table 2  for details regarding Day 1 sample 
collection and evaluations for the local and central laboratory(ies).  
n Subjects who meet all inclusion criteria and none of the exclusion criteria to th e satisfaction of the Investigator, including  the screening 
ECG and the screening urine pregnancy test, will be eligible to enter the study and w ill be randomized 1:[ADDRESS_1198942] random ization will be stratified by [CONTACT_860192]/COPD. 
o Eligible subjects will receive an el ectronic data capture handheld device (ERT® eCOA Handheld eDiary) on Day 1 and will return the 
device to the study site at the EOS Visit. Refer to Section 7.1.2  for additional details. 
p The RSV symptom diary will be self-com pleted by [CONTACT_860193] ±[ADDRESS_1198943] takes a cetaminophen or 4 hours after taking acetaminophen. 
  
  
s Study drug (EDP-938 or placebo) should be  administered at the study site on Days  [ADDRESS_1198944] the date and tim e of any 
acetaminophen use. See Section 5.8  for additional details on acetaminophen use.  
